Ivonescimab Injection，依沃西单抗注射液

Generic name Ivonescimab Injection
Trade name Idafang
English name Ivonescimab Injection
Registered specification 100mg (10mL) / bottle
Indications
Combined with pemetrexed and carboplatin, for the treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with positive EGFR gene mutations that have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
Dosage 20mg/kg intravenous infusion once every 3 weeks
Main advantages compared with reference drugs: ① The new and original bifunctional quadrivalent antibody mechanism, compared with the combination drug, the affinity of the quadrivalent antibody drug with the target is exponentially improved, which can achieve efficient synergy of immunity and anti-angiogenesis in tumor tissues, and double kill tumors ② This product has a significant trend of improving patient survival benefits, while the reference drug has no survival benefit trend ③ Significantly reduce adverse reactions, especially gastrointestinal perforation, bleeding, hypertension, proteinuria, etc. related to anti-angiogenesis; the incidence of drug discontinuation is low, and no TRAEs leading to death have occurred
6 patents have been authorized, the main patents are as follows
CN109053895A Anti-PD-1 and anti-VEGFA bifunctional antibodies,
their pharmaceutical compositions and uses
ANTI-PD-1/VEGFA
BIFUNCTIONAL ANTIBODY, PHARMACEUTICAL
COMPOSITION THEREOF AND
USE THEREOF
WO2020043184A1
US20210340239A1
EP3882275A1
CN112830972A Anti-PD-1-anti-VEGFA bifunctional antibodies,
their pharmaceutical compositions and uses
ANTI-PD-1/VEGFA BISPECIFIC
ANTIBODY, PHARMACEUTICAL
COMPOSITION THEREOF AND
USE THEREOF
WO2021104302A1
US20230027029A1
EP4067387A1
Main innovationsØ A new and original bifunctional tetravalent antibody mechanism. Compared with combination therapy, the affinity of tetravalent antibody drugs to targets is exponentially improvedØ Through the bifunctional design of a single molecule, the distribution difference of PD-1 and VEGF between tumor tissue and normal tissue can be utilized to achieve simultaneous improvement of efficacy and safety
Efficacy or safety advantages brought by this innovationØ The simultaneous inhibition of PD-1 and VEGF can achieve efficient synergy of immunity and anti-angiogenesis in tumor tissue, and double kill tumorsØ The distribution concentration in tumor tissue is much higher than that in normal tissue. In addition to more precise efficacy, it can also greatly reduce adverse reactions, especially the incidence of adverse reactions such as gastrointestinal perforation, bleeding, hypertension, proteinuria, etc. related to anti-VEGF is greatly reduced